Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart IL-1 inhibitor in elderly gouty arthritis flares
ChiCTR2600119982Phase 4Not yet recruiting
- Sponsor
- Hebei General Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of genakumab in gout and acute gout flare, sponsored by Hebei General Hospital. Primary endpoint: Recurrence rate of acute gouty arthritis flares within 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
genakumab
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on ChiCTR2600119982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119982.